article thumbnail

DNA Analysis Finds New Target for Diabetes Drugs

NIH Director's Blog: Drug Development

Credit: Jane Ades, National Human Genome Research Institute, NIH Type 2 diabetes (T2D) tends to run in families, and over the last five years the application of genomic technologies has led to discovery of more than 60 specific DNA variants that contribute to risk. 2010 Jan-Feb;2(1):49-50. [7] J Clin Invest.

DNA 52
article thumbnail

New insight into BRCA2 gene mutations and cancer risk

Drug Target Review

Researchers from the University of California, Davis delved deeper into the mechanisms of DNA repair and cancer development by studying the BRCA2 gene at the molecular level. The study’s findings provide new insights into the origins of cancer and DNA repair mechanisms.

DNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Afimetoran

New Drug Approvals

11:373-384 (2010)). 10:89-102 (2010)). TLR7-9 are among the set that are endosomally located and respond to single-stranded RNA (TLR7and TLR8) or unmethylated single-stranded DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). Nature Immunol., With the exception of TLR3, all TLRs recruit the adaptor molecule MyD88.

RNA 62
article thumbnail

Key considerations before commencing cell line development

Drug Target Review

After binding, the transposase enzyme will excise the flanked section of DNA (termed the transposon) and insert it into sites in the genome at specific target sequences. An example of the former includes a report in the journal Nature of a new tool that can increase the amount of DNA that can be inserted using CRISPR-Cas9 technology.

article thumbnail

The evolution of cell therapy to address unmet medical needs

Drug Target Review

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. This provides some regulatory advantages, and of course, significant cost advantages.

article thumbnail

Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board

The Pharma Data

Pamer joined the University of Chicago from Memorial Sloan Kettering Cancer Center in New York City, where he served as head of the Division of Subspecialty Medicine from 2011 to 2018 and director of the Center for Microbes, Inflammation and Cancer from 2010 to 2019.

article thumbnail

AstraZeneca unveils The Discovery Centre (DISC) in Cambridge

The Pharma Data

Important discoveries have included Francis Crick and James Watson’s DNA advance in 1953, and Professor Sir John Gurdon’s work on stem cells in 2012. Over the once century, roughly 50 Nobel Prize winners in chemistry and physiology or drug have been associated with Cambridge. region in the US, and Gothenburg in Sweden.